LONDON - Britain's GlaxoSmithKline PLC says it has completed its $3.6 billion acquisition of U.S. biotech company Human Genome Sciences.
In a statement Friday, the pharmaceutical and consumer goods group says all outstanding shares were bought for $14.25 each in cash.
Human Genome Sciences, based in Rockville, Md., agreed to the acquisition last month after GSK raised its bid price from $13 a share.
Under the agreement, GSK gains full ownership of two experimental drugs plus Human Genome's only marketed medicine, Benlysta. That's the first new drug approved in about 50 years for lupus, a chronic immune disorder.
GSK expects the deal to add to core earnings from next year and to produce at least $200 million in cost savings by 2015.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
"Sulu" weighs in on the actor filling his shoes in the new "Star Trek."
A Philadelphia bicyclist has teamed up with a cat for tandem rides.
Snooki awkwardly meets "Jersey Shore" nemesis Chris Christie.
Morgan Freeman can't stay awake during a TV interview. (Video)